Clinical Studies in Patients with Solid Tumors using a Second-Generation Antisense Oligonucleotide (GEM®231) Targeted against Protein Kinase A Type I

Annals of the New York Academy of Sciences

Volumn 1002, Issue , 2003, Pages 252-262

  Mani, S ^a,b,c,j   Goel, S ^a,b,c   Nesterova, M ^d   Martin, R M ^e   Grindel, J M ^f   Rothenberg, M L ^g   Zhang, R ^h   Tortora, G ⁱ   Cho Chung, Y S ^d  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b Department of Oncology ^*  (United States)

^c ALBERT EINSTEIN CANCER CENTER   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e HYBRIDON INC   (United States)

^f EPD Pharma Solutions   (United States)

^g VANDERBILT INGRAM CANCER CENTER   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁱ UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^j Jack D Weiler Hospital   (United States)

more..

Author keywords

Antisense; Mixed backbone; Oligonucleotide; PKA type I; Solid tumors

Indexed keywords

ANTIESTROGEN; CAMPTOTHECIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE 1; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; CYTOTOXIC AGENT; DOCETAXEL; GENE EXPRESSION MODULATOR 231; IRINOTECAN; PACLITAXEL; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

BLEEDING; CANCER PATIENT; CLINICAL STUDY; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEVER; GYNECOLOGIC CANCER; HUMAN; LUNG CANCER; MOLECULAR INTERACTION; NEUROPATHY; NEUTROPENIA; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA;

EID: 1342289728     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1281.028     Document Type: Conference Paper

References (34)

1. DE SMET, M.D., C.J. MEENKE & G.J. VAN DEN HOEM. 1999. Formivirsen: a phosphorothioate oligonucleotide for the treatment of CMV retinitis. Ocul. Immunol. Inflamm. 7: 189-198.
2. TAMM, I., B. DORKEN & G. HARTMANN. 2001 Antisense therapy in oncology: new hope for an old idea. Lancet 358: 489-497.
3. CROOKE, S.T. 2000. Potential role of antisense technology in oncology. Oncogene 19: 6651-6659.
4. AGRAWAL, S. & E.R. KANDIMALLA. 2000. Antisense therapeutics: is it as simple as complementary base recognition? Mol. Med. Today. 2: 72-81.
5. WANG, H., G. PRASAD, J.K. BUOLAMWINI & R. ZHANG. 2001. Antisense anticancer oligonucleotide therapeutics. Curr. Cancer Drug Targets 3: 177-196.
6. AGRAWAL, S. & E.R. KANDIMALLA. 2001. Antisense and/or immunostimulatory oligonucleotide therapeutics. Curr. Cancer Drug Targets 3: 197-209.
7. CHO-CHUNG, Y.S. 2002. Antisense DNAs as targeted therapeutics for cancer: no longer a dream. Curr. Opin. Invest. Drug. 3: 934-939.
8. NESTEROVA, M. & Y.S. CHO-CHUNG. 1995. A single-injection protein kinase A-directed antisense treatment to inhibit tumor growth. Nat. Med. 1: 528-633.
9. AGRAWAL, S. & Q. ZHAO. 1998. Mixed backbone oligonucleotides: improvement in oligonucleotide-induced toxicity in vivo. Antisense Nucleic Acid Drug Dev. 8: 135-139.
10. BRAMSON, H.N., E.T. KAISER & A.S. MILDVAN. 1983. Mechanistic studies of cAMP-dependent protein kinase actions. Crit. Rev. Biochem. 15: 93-124.
11. KREBS, E.G. & J.A. BEAVO. 1979. Phosphorylation-dephosphorylation of enzymes. Annu. Rev. Biochem. 48: 923-939.
12. BEEBE, S.J. & J.D. CORBIN, EDS. 1986. Cyclic nucleotide-dependent protein kinases. In The Enzymes: Control by Phosphorylation. Academic Press. New York, pp. 43-111.
13. CHO-CHUNG, Y.S. 1998. Protein kinase A-directed antisense blockade of cancer growth: single gene-based therapeutic approach. In Applied Antisense Oligonucleotide Technology. C.A. Stein & A.M. Krieg, Eds.: 263-281. Wiley-Liss. New York.
14. CHO-CHUNG, Y.S., M. NESTEROVA, S. PEPE, et al. 1999. Antisense DNA-targeting protein kinase A-RIα subunit: a novel approach to cancer treatment. Front. Biosci. 4: d898-d868.
15. TORTORA, G. & F. CIARDIELLO. 2002. Protein kinase A as target for novel integrated strategies of cancer therapy. Ann. N. Y Acad. Sci. 968: 139-147.
16. MILLER, WR. 2002. Regulatory subunits of PKA and breast cancer. Ann. N. Y. Acad. Sci. 968: 37-48.
17. MILLER, W.R., M.J. HULME, J.M. BARTLETT, et al. 1997. Changes in messenger RNA expression of protein kinase A regulatory subunit ialpha in breast cancer patients treated with tamoxifen. Clin. Cancer Res. 12(Pt. 1): 2399-2404.
18. WANG, H., Q. CAI, X. ZENG, et al. 1999. Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIα subunit of protein kinase A after oral administration. Proc. Natl. Acad. Sci. USA 24: 13989-13994.
19. NESTEROVA, M. & Y.S. CHO-CHUNG. 2000. Oligonucleotide sequence-specific inhibition of gene expression, tumor growth inhibition, and modulation of cAMP signaling by an RNA-DNA hybrid antisense targeted to protein kinase A RIα subunit. Antisense Nucleic Acid Drug Dev. 6: 423-433.
20. CHO, Y.S., M.K. KIM, L. TAN, et al. 2002. Protein kinase A RIα antisense inhibition of PC3M prostate cancer cell growth: Bcl-2 hyperphosphorylation, Bax up-regulation, and Bad-hypophosphorylation. Clin. Cancer Res. 8: 607-614.
21. WANG, H., J. HANG, Z. SHI, et al. 2002. Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, pharmacokinetics and host toxicity. Int. J. Oncol. 1: 73-80.
22. CHO, Y.S. & Y.S. CHO-CHUNG. 2003. Antisense protein kinase A RIα acts synergistically with hydroxycamptothecin to inhibit growth and induce apoptosis in human cancer cells: molecular basis for combinatorial therapy. Clin. Cancer Res. 9: 1171-1178.
23. AGRAWAL S., E.R. KANDIMALLA, D. YU, et al. 2002. GEM 231, a second-generation antisense agent complementary to protein kinase A RIalpha subunit, potentiates anti-tumor activity of irinotecan in human colon, pancreas, prostate and lung cancer xenografts. Int. J. Oncol. 1: 65-72.
24. CHEN, H.X., J.L. MARSHALL, E. NESS, et al. 2000. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors. Clin. Cancer Res. 4: 1259-1266.
25. CHO, Y.S., Y.G. PARK, Y.N. LEE, et al. 2000. Extracellular protein kinase A as a cancer biomarker: its expression by tumor cells and reversal by a myristate-lacking Calpha and RIIbeta subunit overexpression. Proc. Natl. Acad. Sci. USA 97: 835-840.
26. CVIJIC, M.E., T. KITA, W. SHIH, et al. 2000. Extracellular catalytic subunit activity of the cAMP-dependent protein kinase in prostate cancer. Clin. Cancer Res. 6: 2309-2317.
27. CHO, Y.S., Y.N. LEE & Y.S. CHO-CHUNG. 2000. Biochemical characterization of extracellular cAMP-dependent protein kinase as a tumor marker. Biochem. Biophys. Res. Commun. 278: 679-684.
28. SIMON, R., B. FREIDLIN, L. RUBINSTEIN, et al. 1997. Accelerated titration designs for phase I clinical trials in oncology. J. Natl. Cancer Inst. 89: 1138-1147.
29. CHO-CHUNG, Y.S., M. NESTEROVA, K.G. BECKER, et al. 2002. Dissecting the circuitry of protein kinase A and cAMP signaling in cancer genesis: antisense, microarray, gene overexpression, and transcription factor decoy. 968, Ann. N. Y Acad. Sci. 968: 22-36.
30. ROHLFF, C. & R.I. GLAZER. 1998. Regulation of the MDR1 promoter by cyclic AMP-dependent protein kinase and transcription factor SpI. Int. J. Oncol. 12: 383-386.
31. LOCKHART, A.C., C. RUDIN, J.D. BERLIN, et al. 2003. GEM231, a second-generation anti-PKA oligonucleotide, administered with weekly CPT-II:A phase I trial. Proc. Am. Soc. Clin. Oncol. 22: In press.
32. MANI, S., Y. GU, S. WADLER & H. FINGERT. 1999. Antisense therapeutics in oncology: points to consider in their clinical evaluation. Antisense Nucleic Acid Drug Dev. 9: 543-547.
33. HOLMLUND, J.T., B.P. MONIA, T.J. KWOH & F.A. DORR. 1999. Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development. Curr. Opin. Mol. Ther. 3: 372-385.
34. RUDIN, C.M., J. HOLMLUND, G.F. FLEMING, et al. 2001. Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. Clin. Cancer Res. 7: 1214-1220.